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Abstract
Aromatase inhibitors effectively delay epiphysial maturation in boys and improve testosterone levels in adult men
Therefore, aromatase inhibitors may be used to increase adult height in boys with gonadotropin-independent
precocious puberty, idiopathic short stature and constitutional delay of puberty. Long-term efficacy and safety of
the use of aromatase inhibitors has not yet been established in males, however, and their routine use is therefore
not yet recommended.
Background
Over the past 15 years it has become evident that in
men estradiol is responsible for a number of effects ori-
ginally attributed to testosterone. Estradiol has an
important role in gaining and maintaining bone mass,
closing of the epiphyses and the feedback on gonadotro-
pin secretion. This fact became particularly evident in
men with aromatase deficiency. Aromatase is the
enzyme responsible for conversion of androgens to
estrogens. Men with estrogen deficiency caused by a
mutation in the CYP19 gene suffer from low bone
mineral density (BMD) and unfused epiphyses, and have
high gonadotropin and testosterone levels [1]. Estrogen
excess in turn has been associated with premature clo-
sure of the epiphyses, gynecomastia and low gonadotro-
pin and testosterone levels. Lowering estrogen levels in
men has emerged, consequently, as a potential treatment
for a number of disorders including pubertas praecox,
the andropause (also referred to as late-onset hypogo-
nadism) and gynecomastia. Aromatase inhibitors were
proven to be safe, convenient and effective for the treat-
ment of hormone sensitive breast cancer in women
although their use is associated with a modest increase
in bone resorption [2,3]. This review will discuss the
potential targets and the evidence for the use of aroma-
tase inhibitors in men and adds more recent data to the
text of an earlier review on this subject [4].
Metabolism of estrogens in men
Aromatase, also known as estrogen synthetase, is the
key enzyme in estrogen biosynthesis. The enzyme, loca-
lized in the endoplasmic reticulum of the estrogen-pro-
ducing cell, is encoded by the CYP19A1 gene. This gene
is a member of the CYP gene family, encoding a class of
enzymes active in the hydroxylation of endogenous and
exogenous substances. The CYP19A1 gene is localized
on chromosome 15 and comprises nine exons; the start
codon for translation is located on exon 2. Transcription
of the aromatase gene is regulated by several tissue-spe-
cific promoters. These promoters are under the influ-
ence of different hormones and growth factors such as
gonadotropins (gonadal promoter II) and interleukin-6,
interleukin-11 and tumor necrosis factor-a (adipose/
bone promoter I.4; for review see [5]). Aromatase activ-
ity has not only been demonstrated in gonads and pla-
centa but also in brain [6], fat tissue [7,8], muscle [9],
hair [10], bone [11] and vascular tissue [12].
Estradiol is the most potent estrogen produced in the
body. It is synthesized from testosterone or estrone via
aromatase or 17b-hydroxysteroid dehydrogenase, respec-
tively. The total estradiol production rate in the human
male has been estimated to be 35-45 μg (0.130-0.165
μmol) per day, of which approximately 20% is directly
produced by the testes [13,14]. Roughly 60% of circulat-
ing estradiol is derived from direct testicular secretion
or from conversion of testicular androgens. The remain-
ing fraction is derived from peripheral conversion of
adrenal androgens [15]. The mean estradiol plasma con-
centration in men is only about 1/200 of the mean
plasma testosterone concentration [16] and is
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comparable to estradiol levels found in women in the
early follicular phase of the menstrual cycle.
Phenotype of aromatase deficiency and excess
To date, eight males with aromatase deficiency have
been described: seven adults [17-23] and one newborn
[24]. Estradiol levels in these males were extremely low.
All adult aromatase-deficient men demonstrated a
remarkably low bone mass and unfused epiphyses lead-
ing to linear growth into adulthood and above-average
body length. Testicular size in these men ranged from
micro- to macroorchidism and the plasma testosterone
levels varied roughly in accordance with testis size.
Levels of luteinizing hormone (LH) were either normal
or elevated. Four men were infertile, in one younger
male fertility was not described. Two aromatase-defi-
cient men had a brother who also suffered from inferti-
lity despite a normal aromatase genotype, suggesting an
unrelated second condition. Once treated with estradiol,
epiphyses closed, BMD increased and disturbances in
the lipid profile improved in most of these patients.
On the other hand, several, mostly familial cases of aro-
matase excess have been reported. The clinical picture
consists of gynecomastia, accelerated growth and prema-
ture bone maturation due to excessive peripheral estrogen
synthesis. Stratakis et al. [25] described a family with aro-
matase excess syndrome in which the syndrome appeared
to be caused by inappropriately high expression of an
alternative first exon. Shozu et al. [26] described a father
and his son and one unrelated patient with aromatase
excess caused by a chromosomal rearrangement, which
placed the aromatase gene adjacent to cryptic promoters.
As a result an inappropriate amount of aromatase was
expressed in adipose tissue of the affected subjects.
These case reports illustrate the important contribu-
tion of estrogens to male health and identify the possi-
ble indications and risks of aromatase-inhibitor
treatment in men. Aromatase inhibitors may be used to
treat or prevent gynecomastia. They may be used to
increase gonadotropin secretion and thereby stimulate
Leydig and Sertoli cell function. Aromatase inhibitors
may be used to prevent or delay epiphysial closure and
thereby increase adult height. A major concern of aro-
matase inhibition is the possible detrimental effect on
bone mineralization.
Aromatase inhibitors
Aromatase inhibitors are classified as either steroidal or
nonsteroidal, or as first, second or third generation. Ster-
oidal inhibitors such as formestane and exemestane inhi-
bit aromatase activity by mimicking the substrate
androstenedione. Nonsteroidal enzyme inhibitors such as
anastrozole and letrozole inhibit enzyme activity by bind-
ing with the heme iron of the enzyme. First-generation
aromatase inhibitors such as aminoglutethimide are rela-
tively weak and nonspecific; they can also block other
steroidogenic enzymes necessitating adrenal steroid sup-
plementation. Third-generation inhibitors such as letro-
zole and anastrozole are potent and do not inhibit related
enzymes. They are well tolerated and apart from their
effects on estrogen metabolism their use does not appear
to be associated with important side effects in postmeno-
pausal women [27]. Although aromatase inhibition by
anastrozole and letrozole is reported to be close to 100%,
administration of these inhibitors to men will not sup-
press plasma estradiol levels completely. In men third-
generation aromatase inhibitors will decrease the mean
plasma estradiol/testosterone ratio by 77% [28,29]. This
finding probably relates to the high plasma concentra-
tions of testosterone, a major precursor for estradiol
synthesis in adult men. As aromatase inhibition is dose
dependent it has been suggested that aromatase is less
suppressed in the testis compared to adipose and muscle
tissue, explaining the incomplete efficacy of aromatase
inhibition in men. Aromatase activity is high in the testes
and the molar ratio of testosterone to letrozole is much
higher in the testes compared with adipose and muscle
tissue. When testicular testosterone and estradiol synth-
esis are suppressed and testosterone is administered exo-
genously in combination with letrozole, however, the
estradiol/testosterone ratio is suppressed by 81% [30],
which is only marginally different from the suppression
of this ratio in intact men after treatment with letrozole.
This incomplete suppression may be regarded as advan-
tageous for it prevents excessive reduction of estrogen
levels in men and the possible associated adverse effects.
In postmenopausal women with breast carcinoma, long-
term use of potent aromatase inhibitors reduces circulat-
ing estradiol levels by 88% [31] and is associated with
adverse effects on bone [2,3]. Due to the much higher
estrogen levels in treated men it remains to be deter-
mined whether this also holds true for men.
Effects of aromatase inhibition on luteinizing hormone
release and testosterone production
It is well known from experimental evidence and from
clinical observations that estradiol has powerful effects
on gonadotropin release in men. Modulation of plasma
estradiol levels within the male physiological range is
associated with strong effects on plasma levels of LH
through an effect at the level of the pituitary gland [32].
Lowering estradiol levels, by administering an aromatase
inhibitor, is associated with an increase in levels of LH,
follicle-stimulating hormone (FSH) and testosterone
[28,29]. Aromatase inhibitors, therefore, have been sug-
gested as a tool to increase testosterone levels in men
with low testosterone levels. Due to their mode of action
the use of aromatase inhibitors is limited to men with at
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least some residual function of the hypothalamo-pitui-
tary-gonadal axis. Therefore aromatase inhibitors have
been tested in older men suffering from so-called late-
onset hypogonadism or partial androgen deficiency.
Aging in men is associated with a gradual decline of
total and free testosterone levels [33] as a result of com-
bined testicular and hypothalamic dysfunction. The
decline of testosterone levels has been implicated in the
pathogenesis of physical frailty in older men. Androgen
treatment, therefore, has been advocated for older men
with signs and symptoms of androgen deficiency and
unequivocally low plasma testosterone levels [34,35].
Aromatase inhibitors may be an attractive alternative
for traditional testosterone substitution in elderly men
because these compounds can be administered orally
once daily and may result in physiological 24 h testoster-
one profiles. Additionally, misuse of aromatase inhibitors
is unlikely since testosterone levels will not be stimulated
to vastly supraphysiological levels. A small, controlled
study demonstrated that anastrozole in a dose of 1 mg
daily during 12 weeks will result in doubling of the mean
bioavailable testosterone level in older men [36]. A more
recent study also showed a moderate but significant
effect of aromatase inhibition on estradiol and testoster-
one levels in older men [37]. Treatment with atamestane
100 mg once daily resulted in a 40% increase in total tes-
tosterone levels after 36 weeks. However, no beneficial
effects were seen on muscle strength, body composition
or quality-of-life scores. A similar increase of testosterone
levels in the absence of effects on body composition and
strength was reported in a study, in which elderly men
with borderline low levels of serum testosterone were
treated with anastrozole during 1 year [38]. There is a
number of possible explanations for the lack of a clear
treatment effect. First of all, the numbers of studied sub-
jects were relatively small. Moreover, the mean baseline
testosterone levels in the treated groups were in, or only
slightly below, the normal range for young adult men and
the relative increase in testosterone levels may have been
too small. It has been suggested that men with the lowest
baseline testosterone levels benefit most from testoster-
one substitution [39]. Finally, the decreased levels of
estradiol may have affected the expected rise in lean body
mass [38]. These observations outline a serious limitation
of the use of aromatase inhibitors in older men; the sti-
mulating effect on testosterone levels may be too weak,
especially in the men with the lowest baseline testoster-
one levels who would potentially benefit most.
Effects of aromatase inhibition in obese men
Peripheral androgen aromatization is enhanced in sub-
jects with increased body mass index [40]. Massively
obese men show markedly increased plasma estradiol
concentrations and low testosterone concentrations [41].
In three small studies, letrozole or testolactone has been
administered to morbidly obese men to improve their
testosterone levels [42-44]. Treatment resulted in nor-
malization of testosterone levels in all subjects, with a
concomitant suppression of the originally increased
levels of estradiol. This normalization of the estradiol/
testosterone ratio might be of advantage, because of the
suppressive effects of testosterone on the expression of
the estrogen receptor b, which in itself, in the presence
of high levels of estradiol, can suppress the expression
of GLUT-4, leading to insulin insensitivity [45]. A case
study describes a morbidly obese infertile man, who
after a similar treatment with anastrozole showed a nor-
malized pituitary-testis axis, spermatogenesis and ferti-
lity [46]. However, testosterone levels will also improve
on weight loss [47], which is the intervention of choice
for obese men with or without low testosterone levels.
Effects of aromatase inhibition on release of follicle-
stimulating hormone and spermatogenesis
Although FSH release is primarily under the control of
inhibin, circulating estradiol has a substantial effect on
FSH levels in men [28]. Aromatase inhibition results in a
three-fold increase in levels of FSH [28,29] in eugonadal
men and may potentially stimulate sperm production.
Earlier studies using tamoxifen or clomifene to increase
FSH levels did not show unequivocal evidence for the
efficacy of this approach [48]. Uncontrolled studies using
anastrozole, testolactone or letrozole have shown some
evidence for a positive effect on sperm concentration and
motility [49-51]. However, one double-blind crossover
trial using testolactone did not show a significant
improvement of sperm quality in men with oligospermia
[52]. More recently, a study in which anastrozole was
added to the treatment with tamoxifen in men with idio-
pathic oligoasthenoteratozoospermia and a decreased tes-
tosterone over estradiol ratio after treatment with
tamoxifen alone indicated an increased pregnancy rate
compared with the group without the addition of the aro-
matase inhibitor [53]. Finally, pretreatment with aroma-
tase inhibitors was described to lead to positive results of
testicular sperm extraction in Klinefelter’s syndrome
patients with low pretreatment testosterone concentra-
tions: men from whose testes spermatozoa were retrieved
showed higher posttreatment testosterone levels and tes-
tosterone over estradiol ratios compared to men in
whom no spermatozoa could be obtained, whereas pre-
treatment levels of testosterone, LH and FSH did not pre-
dict the result of treatment outcome [54].
Effects of aromatase inhibition on bone metabolism and
epiphysial closure
Estrogens are essential for epiphysial maturation in boys.
Aromatase inhibitors, therefore, may be used to lower
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estradiol levels and thereby slow down epiphysial
maturation. This approach proved successful in rare
conditions such as the aromatase-excess syndrome [25]
and high estrogen levels due to Sertoli cell tumors in
boys with Peutz-Jeghers syndrome [55]. In boys with
familial male precocious puberty due to activating muta-
tions of the LH receptor, also known as testotoxicosis,
treatment with an antiandrogen in combination with an
aromatase inhibitor to prevent effects on bone is the
treatment of choice. In an earlier study a combination
of spironolactone and testolactone proved effective [56],
whereas in later studies the combination of bicalutamide
and anastrozole was used [57-59].
Aromatase inhibition has also been studied in boys
with idiopathic short stature. Boys with a mean age of
11 years at the start of the study were treated with letro-
zole 2.5 mg once daily or placebo for 2 years [60].
Letrozole treatment was associated with higher plasma
levels of gonadotropins and testosterone in boys who
entered puberty during the study. In spite of this fact,
plasma estradiol levels were mostly lower in the letro-
zole-treated group. Both groups showed similar growth
velocity but bone age progressed significantly slower in
the letrozole group resulting in a gain of 5.9 cm in pre-
dicted adult height. The fact that growth velocity was
not affected is remarkable in the light of the observa-
tion, that in adult men treated with a combination of
testosterone and anastrozole the responses to GH secre-
tagogues were smaller than in men treated with a com-
bination of testosterone and a placebo; the GH and
IGF-1 concentrations were positively correlated with
estradiol levels [61]. Also in letrozole-treated boys in
whom treatment started at the beginning of puberty,
IGF-I levels were lower than in placebo-treated controls
[62]. As expected, GH-deficient boys treated with GH
and anastrozole showed a larger increase in height than
their GH only-treated controls [63].
Boys with constitutional delay of puberty are typically
small for their age and final adult height is often in the
low-normal range. These boys may be treated with
androgens to induce puberty. Although testosterone
induces growth velocity, the estrogens aromatized from
testosterone will accelerate epiphysial maturation and
for that reason reduce adult height further. The combi-
nation of testosterone and letrozole, therefore, was
tested in boys with constitutional delay of puberty. This
combination treatment effectively increased growth velo-
city but epiphysial maturation was slower in the letro-
zole-treated group, leading to a significant increase in
predicted adult height [64,65].
Effects of aromatase inhibition on male breast
Aromatase inhibitors are widely prescribed for hormone-
responsive breast carcinoma in postmenopausal women.
It is well known that aromatase inhibition results in a
dramatic reduction of tumor estrogen concentrations
[66]. As gynecomastia in men presumably results from
an imbalance between androgen and estrogen action,
aromatase inhibition was tested as a treatment for gyne-
comastia in boys. Treatment with anastrozole daily for 6
months, however, did not result in a significant improve-
ment compared with placebo [67]. This is in accordance
with the data summarized in a recent review [68],
describing similar responses to placebo, tamoxifen and
anastrozole in a number of observational studies. Ana-
strozole was also studied in a group of prostate cancer
patients treated with bicalutamide, an androgen antago-
nist. A dose of 1 mg daily appeared to be mildly effective
against the appearance of gynecomastia. Tamoxifen was
much more effective, however, in the prevention of gyne-
comastia in these men [69,70]. Due to these disappoint-
ing results, aromatase inhibitors are not recommended as
a first-line treatment for gynecomastia in men.
Data on treatment of male mammary tumors with
aromatase inhibitors are scarce and indicate that this
treatment modality is unlikely to be successful because
of the unwanted effect of increased levels of testoster-
one, making it impossible to reach the low estradiol
levels obtained in postmenopausal women after this
treatment [71]. The combination with a GnRH analog
in order to prevent this increase did not yield beneficial
results either [72].
Safety and concerns for aromatase inhibitors in men
Extensive experience with third-generation aromatase
inhibitors in postmenopausal women did not reveal
major side effects related to their use. Long-term use in
postmenopausal women is associated with a moderate
increase in bone resorption and a modest decrease in
BMD compared with placebo [2,3]. As outlined above,
low BMD is a characteristic sign of aromatase deficiency
but also in normal men most cross-sectional studies
showed that bioavailable or total estradiol levels are
associated with BMD [73-77]. The primary concern,
therefore, associated with aromatase inhibition in men is
the negative effect it may have on bone metabolism. In
most studies utilizing aromatase inhibitors in men estra-
diol levels decreased only moderately. Additionally, the
suppression of plasma estradiol levels in men is asso-
ciated with an increase in gonadotropin levels, which
stimulate the production of testosterone, the main pre-
cursor for estradiol synthesis. Khosla et al. [76,78] pro-
posed a threshold for bioavailable estradiol of 30 pM,
below which BMD appeared to be strongly and nega-
tively associated with the plasma bioavailable estradiol
concentration in men. Thresholds should be interpreted
with great caution because they rely heavily on the
methods used to measure total or bioavailable estradiol
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levels. These authors used ammonium sulfate precipita-
tion to measure bioavailable estradiol levels whereas if
they had calculated bioavailable estradiol levels using
the popular Sodergard equation [79,80] their proposed
threshold may have been as high as 75 pM. In experi-
mental settings, selective withdrawal of estradiol in men
was associated with an increase in markers of bone
resorption [30,81]. In the studies published so far aro-
matase inhibition in men did not appear to be asso-
ciated with adverse effects on bone in a number of
studies [37,59,82,83], but in a more recent study a
decrease of spine BMD was observed after one year of
treatment of elderly men with anastrozole [84]. Addi-
tionally, one short-term study did not show adverse
effects of aromatase inhibition in older men on cardio-
vascular markers. However, it is not clear that this con-
clusion also holds for boys: vertebral deformities were
observed in boys treated for delayed onset of puberty
[85]. Furthermore, hyperandrogenism induced by treat-
ment with aromatase inhibitors may result in decreased
HDL-cholesterol and increased hemoglobin levels [86],
indicating the need for follow-up during treatment. The
same group of investigators concluded that there were
no effects of letrozole on cognitive performance could
be detected in a group of prepubertal boys [87]. In a
group of elderly men who obtained exogenous testoster-
one enenthate, the addition of anastrozole to the
injected androgen prevented the androgen induced
improvement of verbal memory, but did not affect spe-
cial memory [88].
Conclusion
Over the years compelling evidence has accumulated
that in men estradiol has an important role in gaining
and maintaining bone mass, closing of the epiphyses
and feedback on gonadotrophin release. Aromatase inhi-
bitors, mostly combined with agonists of gonadotro-
phin-releasing hormone proved effective for the
prevention of premature epiphysial closure in boys with
pubertas praecox of various etiologies. There is also evi-
dence that aromatase inhibitors can be used in boys
with idiopathic short stature and boys with constitu-
tional delay of puberty to increase adult height. Aroma-
tase inhibitors are not effective for the treatment of
gynecomastia in pubertal boys and have limited efficacy
for the prevention of gynecomastia in bicalutamide-trea-
ted men with prostate cancer. Although aromatase inhi-
bitors increase FSH levels, there is no consistent
evidence for a beneficial effect on spermatogenesis. In
older men with so-called late-onset hypogonadism, aro-
matase inhibitors may emerge as an attractive alternative
for traditional testosterone supplementation to improve
testosterone levels. The long-term benefits of higher tes-
tosterone levels in older men remain controversial,
however. Moreover, it is questionable whether aroma-
tase inhibitors are able to stimulate testosterone produc-
tion sufficiently in men with truly low testosterone
levels for whom testosterone treatment is currently
recommended. Although most of the recent studies with
aromatase inhibitors in boys and adult men do not
show major detrimental effects on bone long-term skele-
tal safety remains an issue of concern.
Author details
1Department of Internal Medicine, Kennemer Gasthuis, P.O. Box 417, 2000 AK
Haarlem, The Netherlands. 2Department of Internal Medicine, Erasmus
university Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The
Netherlands.
Authors’ contributions
WDR wrote the original version of this manuscript. FHDJ extended the text
with more recent observations and conclusions. Both authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 1 March 2011 Accepted: 21 June 2011
Published: 21 June 2011
References
1. Jones ME, Boon WC, McInnes K, Maffei L, Carani C, Simpson ER:
Recognizing rare disorders: aromatase deficiency. Nat Clin Pract
Endocrinol Metab 2007, 3:414-421.
2. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN,
Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE: Effect of letrozole
versus placebo on bone mineral density in women with primary breast
cancer completing 5 or more years of adjuvant tamoxifen: a companion
study to NCIC CTG MA.17. J Clin Oncol 2006, 24:3629-3635.
3. Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI,
Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G: Effects of
exemestane administered for 2 years versus placebo on bone mineral
density, bone biomarkers, and plasma lipids in patients with surgically
resected early breast cancer. J Clin Oncol 2005, 23:5126-5137.
4. de Ronde W: Therapeutic uses of aromatase inhibitors in men. Curr Opin
Endocrinol Diabetes Obes 2007, 14:235-240.
5. Simpson ER, Davis SR: Minireview: aromatase and the regulation of
estrogen biosynthesis-some new perspectives. Endocrinology 2001,
142:4589-4594.
6. Stoffel-Wagner B, Watzka M, Schramm J, Bidlingmaier F, Klingmüller D:
Expression of CYP19 (aromatase) mRNA in different areas of the human
brain. J Steroid Biochem Mol Biol 1999, 70:237-241.
7. Schindler AE, Ebert A, Friedrich E: Conversion of androstenedione to
estrone by human tissue. J Clin Endocrinol Metab 1972, 35:627-630.
8. Bulun SE, Simpson ER: Competitive reverse transcription-polymerase
chain reaction analysis indicates that levels of aromatase cytochrome
P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of
women increase with advancing age. J Clin Endocrinol Metab 1994,
78:428-432.
9. Longcope C, Pratt JH, Schneider SH, Fineberg SE: Aromatization of
androgens by muscle and adipose tissue in vivo. J Clin Endocrinol Metab
1978, 46:146-152.
10. Schweikert HU, Milewich L, Wilson JD: Aromatization of androstenedione
by isolated human hairs. J Clin Endocrinol Metab 1975, 40:413-417.
11. Schweikert HU, Wolf L, Romalo G: Oestrogen formation from
androstenedione in human bone. Clin Endocrinol (Oxf) 1995, 43:37-42.
12. Harada N, Sasano H, Murakami H, Ohkuma T, Nagura H, Takagi Y: Localized
expression of aromatase in human vascular tissues. Circ Res 1999,
84:1285-1291.
13. Baird DT, Horton R, Longcope C, Tait JF: Steroid dynamics under steady-
state conditions. Recent Prog Horm Res 1969, 25:611-664.
de Ronde and de Jong Reproductive Biology and Endocrinology 2011, 9:93
http://www.rbej.com/content/9/1/93
Page 5 of 7
14. MacDonald PC, Madden JD, Brenner PF, Wilson JD, Siiteri PK: Origin of
estrogen in normal men and in women with testicular feminization. J
Clin Endocrinol Metab 1979, 49:905-916.
15. de Ronde W, Hofman A, Pols HA, de Jong FH: A direct approach to the
estimation of the origin of oestrogens and androgens in elderly men by
comparison with hormone levels in postmenopausal women. Eur J
Endocrinol 2005, 152:261-268.
16. de Ronde W, van der Schouw YT, Muller M, Grobbee DE, Gooren LJ,
Pols HA, de Jong FH: Associations of sex hormone binding globulin
(SHBG) with non-SHBG-bound levels of testosterone and estradiol in
independently living men. J Clin Endocrinol Metab 2005, 90:157-162.
17. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS,
Simpson ER: Effect of testosterone and estradiol in a man with
aromatase deficiency. N Engl J Med 1997, 337:91-95.
18. Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, Clyne CD,
Davis S, Simpson ER, Carani C: Dysmetabolic syndrome in a man with a
novel mutation of the aromatase gene: effects of testosterone,
alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004,
89:61-70.
19. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K: Aromatase
deficiency in male and female siblings caused by a novel mutation and
the physiological role of estrogens. J Clin Endocrinol Metab 1995,
80:3689-3698.
20. Herrmann BL, Saller B, Janssen OE, Gocke P, Bockisch A, Sperling H, Mann K,
Broecker M: Impact of estrogen replacement therapy in a male with
congenital aromatase deficiency caused by a novel mutation in the
CYP19 gene. J Clin Endocrinol Metab 2002, 87:5476-5484.
21. Mittre Hervé MH, Kottler Ml, Pura M: Human gene mutations. Gene
symbol: CYP19. Diseaese: aromatase deficiency. Hum Genet 2004, 114:124.
22. Bouillon R, Bex M, Vanderschueren D, Boonen S: Estrogens are essential
for male pubertal periosteal bone expansion. J Clin Endocrinol Metab
2004, 89:6025-6029.
23. Lanfranco F, Pignatti E, Corneli G, Ghigo E, Aimaretti G, Carani C, Rochira V:
A novel mutation in the human aromatase gene: insights on the
relationship among serum estradiol, longitudinal growth and bone
mineral density in an adult man under estrogen replacement treatment.
Bone 2008, 43:628-635.
24. Deladoëy J, Flück C, Bex M, Yoshimura N, Harada N, Mullis PE: Aromatase
deficiency caused by a novel P450arom gene mutation: impact of
absent estrogen production on serum gonadotropin concentration in a
boy. J Clin Endocrinol Metab 1999, 84:4050-4054.
25. Stratakis CA, Vottero A, Brodie A, Kirschner LS, DeAtkine D, Lu Q, Yue W,
Mitsiades CS, Flor AW, Chrousos GP: The aromatase excess syndrome is
associated with feminization of both sexes and autosomal dominant
transmission of aberrant P450 aromatase gene transcription. J Clin
Endocrinol Metab 1998, 83:1348-1357.
26. Shozu M, Sebastian S, Takayama K, Hsu WT, Schultz RA, Neely K, Bryant M,
Bulun SE: Estrogen excess associated with novel gain-of-function
mutations affecting the aromatase gene. N Engl J Med 2003,
348:1855-1865.
27. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF,
Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I,
Wardley A, Price KN, Goldhirsch A: A comparison of letrozole and
tamoxifen in postmenopausal women with early breast cancer. N Engl J
Med 2005, 353:2747-2757.
28. Raven G, de Jong FH, Kaufman JM, de Ronde W: In men, peripheral
estradiol levels directly reflect the action of estrogens at the
hypothalamo-pituitary level to inhibit gonadotropin secretion. J Clin
Endocrinol Metab 2006, 91:3324-3328.
29. T’sjoen GG, Giagulli VA, Delva H, Crabbe P, De Bacquer D, Kaufman JM:
Comparative assessment in young and elderly men of the gonadotropin
response to aromatase inhibition. J Clin Endocrinol Metab 2005,
90:5717-5722.
30. Falahati-Nini A, Riggs BL, Atkinson EJ, O’Fallon WM, Eastell R, Khosla S:
Relative contributions of testosterone and estrogen in regulating bone
resorption and formation in normal elderly men. J Clin Invest 2000,
106:1553-1560.
31. Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE: Influence of letrozole
and anastrozole on total body aromatization and plasma estrogen levels
in postmenopausal breast cancer patients evaluated in a randomized,
cross-over study. J Clin Oncol 2002, 20:751-757.
32. Pitteloud N, Dwyer AA, DeCruz S, Lee H, Boepple PA, Crowley WF Jr,
Hayes FJ: Inhibition of luteinizing hormone secretion by testosterone in
men requires aromatization for its pituitary but not its hypothalamic
effects: evidence from the tandem study of normal and gonadotropin-
releasing hormone-deficient men. J Clin Endocrinol Metab 2008,
93:784-791.
33. Kaufman JM, Vermeulen A: The decline of androgen levels in elderly men
and its clinical and therapeutic implications. Endocr Rev 2005, 26:833-876.
34. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ,
Swerdloff RS, Montori VM: Testosterone therapy in adult men with
androgen deficiency syndromes: an endocrine society clinical practice
guideline. J Clin Endocrinol Metab 2006, 91:1995-2010.
35. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ,
Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC:
Investigation, treatment and monitoring of late-onset hypogonadism in
males: ISA, ISSAM, and EAU recommendations. Int J Androl 2005,
28:125-127.
36. Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C: Effects of aromatase
inhibition in elderly men with low or borderline-low serum testosterone
levels. J Clin Endocrinol Metab 2004, 89:1174-1180.
37. Muller M, van den Beld AW, van der Schouw YT, Grobbee DE, Lamberts SW:
Effects of dehydroepiandrosterone and atamestane supplementation on
frailty in elderly men. J Clin Endocrinol Metab 2006, 91:3988-3991.
38. Burnett-Bowie SA, Roupenian KC, Dere ME, Lee H, Leder BZ: Effects of
aromatase inhibition in hypogonadal older men: a randomized, double-
blind, placebo-controlled trial. Clin Endocrinol (Oxf) 2009, 70:116-123.
39. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A,
Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG Jr, Strom BL: Effect of
testosterone treatment on bone mineral density in men over 65 years
of age. J Clin Endocrinol Metab 1999, 84:1966-1972.
40. Kley HK, Deselaers T, Peerenboom H, Kruskemper HL: Enhanced conversion
of androstenedione to estrogens in obese males. J Clin Endocrinol Metab
1980, 51:1128-1132.
41. Strain GW, Zumoff B, Miller LK, Rosner W, Levit C, Kalin M, Hershcopf RJ,
Rosenfeld RS: Effect of massive weight loss on hypothalamic-pituitary-
gonadal function in obese men. J Clin Endocrinol Metab 1988,
66:1019-1023.
42. de Boer H, Verschoor L, Ruinemans-Koerts J, Jansen M: Letrozole
normalizes serum testosterone in severely obese men with
hypogonadotropic hypogonadism. Diabetes Obes Metab 2005, 7:211-215.
43. Zumoff B, Miller LK, Strain GW: Reversal of the hypogonadotropic
hypogonadism of obese men by administration of the aromatase
inhibitor testolactone. Metabolism 2003, 52:1126-1128.
44. Loves S, Ruinemans-Koerts J, de Boer H: Letrozole once a week normalizes
serum testosterone in obesity-related male hypogonadism. Eur J
Endocrinol 2008, 158:741-747.
45. Cohen PG: Obesity in men: the hypogonadal-estrogen receptor
relationship and its effect on glucose homeostasis. Med Hypotheses 2008,
70:358-360.
46. Roth MY, Amory JK, Page ST: Treatment of male infertility secondary to
morbid obesity. Nat Clin Pract Endocrinol Metab 2008, 4:415-419.
47. Vermeulen A, Kaufman JM, Giagulli VA: Influence of some biological
indexes on sex hormone-binding globulin and androgen levels in aging
or obese males. J Clin Endocrinol Metab 1996, 81:1821-1826.
48. Vandekerckhove P, Lilford R, Vail A, Hughes E: Clomiphene or tamoxifen
for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 2000, 2:
CD000151.
49. Pavlovich CP, King P, Goldstein M, Schlegel PN: Evidence of a treatable
endocrinopathy in infertile men. J Urol 2001, 165:837-841.
50. Raman JD, Schlegel PN: Aromatase inhibitors for male infertility. J Urol
2002, 167:624-629.
51. Saylam B, Efesoy O, Cayan S: The effect of aromatase inhibitor letrozole
on body mass index, serum hormones, and sperm parameters in
infertile men. Fertil Steril 2011, 95:809-811.
52. Clark RV, Sherins RJ: Treatment of men with idiopathic oligozoospermic
infertility using the aromatase inhibitor, testolactone. Results of a
doubleblinded, randomized, placebo-controlled trial with crossover. J
Androl 1989, 10:240-247.
53. Cakan M, Aldemir M, Topcuoglu M, Altuğ U: Role of testosterone/estradiol
ratio in predicting the efficacy of tamoxifen citrate treatment in
idiopathic oligoasthenoteratozoospermic men. Urol Int 2009, 83:446-451.
de Ronde and de Jong Reproductive Biology and Endocrinology 2011, 9:93
http://www.rbej.com/content/9/1/93
Page 6 of 7
54. Ramasamy R, Ricci JA, Palermo GD, Gosden LV, Rosenwaks Z, Schlegel PN:
Successful fertility treatment for Klinefelter’s syndrome. J Urol 2009,
182:1108-1113.
55. Lefevre H, Bouvattier C, Lahlou N, Adamsbaum C, Bougnères P, Carel JC:
Prepubertal gynecomastia in Peutz- Jeghers syndrome: incomplete
penetrance in a familial case and management with an aromatase
inhibitor. Eur J Endocrinol 2006, 154:221-227.
56. Laue L, Jones J, Barnes KM, Cutler GB Jr: Treatment of familial male
precocious puberty with spironolactone, testolactone, and deslorelin. J
Clin Endocrinol Metab 1993, 76:151-155.
57. Kreher NC, Pescovitz OH, Delameter P, Tiulpakov A, Hochberg Z: Treatment
of familial male-limited precocious puberty with bicalutamide and
anastrozole. J Pediatr 2006, 149:416-420.
58. Reiter EO, Mauras N, McCormick K, Kulshreshtha B, Amrhein J, De Luca F,
O’Brien S, Armstrong J, Melezinkova H: Bicalutamide plus anastrozole for
the treatment of gonadotropin-independent precocious puberty in boys
with testotoxicosis: a phase II, open-label pilot study (BATT). J Pediatr
Endocrinol Metab 2010, 23:999-1009.
59. Lenz AM, Shulman D, Eugster EA, Rahhal S, Fuqua JS, Pescovitz OH,
Lewis KA: Bicalutamide and third-generation aromatase inhibitors in
testotoxicosis. Pediatrics 2010, 126:e728-e733.
60. Hero M, Norjavaara E, Dunkel L: Inhibition of estrogen biosynthesis with a
potent aromatase inhibitor increases predicted adult height in boys
with idiopathic short stature: a randomized controlled trial. J Clin
Endocrinol Metab 2005, 90:6396-6402.
61. Veldhuis JD, Mielke KL, Cosma M, Soares-Welch C, Paulo R, Miles JM,
Bowers CY: Aromatase and 5alpha-reductase inhibition during an
exogenous testosterone clamp unveils selective sex steroid modulation
of somatostatin and growth hormone secretagogue actions in healthy
older men. J Clin Endocrinol Metab 2009, 94:973-981.
62. Hero M, Mäkitie O, Kröger H, Nousiainen E, Toiviainen-Salo S, Dunkel L:
Impact of aromatase inhibitor therapy on bone turnover, cortical bone
growth and vertebral morphology in pre- and peripubertal boys with
idiopathic short stature. Horm Res 2009, 71:290-297.
63. Mauras N, Gonzalez de Pijem L, Hsiang HY, Desrosiers P, Rapaport R,
Schwartz ID, Klein KO, Singh RJ, Miyamoto A, Bishop K: Anastrozole
increases predicted adult height of short adolescent males treated with
growth hormone: a randomized, placebo-controlled, multicenter trial for
one to three years. J Clin Endocrinol Metab 2008, 93:823-831.
64. Wickman S, Sipila I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L: A
specific aromatase inhibitor and potential increase in adult height in
boys with delayed puberty a randomised controlled trial. Lancet 2001,
357:1743-1748.
65. Hero M, Wickman S, Dunkel L: Treatment with the aromatase inhibitor
letrozole during adolescence increases near-final height in boys with
constitutional delay of puberty. Clin Endocrinol (Oxf) 2006, 64:510-513.
66. Van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH: Endogenous
concentration and subcellular distribution of estrogens in normal and
malignant human breast tissue. Cancer Res 1985, 45:2900-2906.
67. Plourde PV, Reiter EO, Jou HC, Desrochers PE, Rubin SD, Bercu BB,
Diamond FB Jr, Backeljauw PF: Safety and efficacy of anastrozole for the
treatment of pubertal gynecomastia: a randomized, double-blind,
placebocontrolled trial. J Clin Endocrinol Metab 2004, 89:4428-4433.
68. Maidment SL: Question 2. Which medications effectively reduce pubertal
gynaecomastia? Arch Dis Child 2010, 95:237-9.
69. Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G,
Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A,
Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V,
Montefiore F: Evaluation of tamoxifen and anastrozole in the prevention
of gynecomastia and breast pain induced by bicalutamide monotherapy
of prostate cancer. J Clin Oncol 2005, 23:808-815.
70. Saltzstein D Sieber P, Morris T, Gallo J: Prevention and management of
bicalutamide-induced gynecomastia and breast pain: randomized
endocrinologic and clinical studies with tamoxifen and anastrozole.
Prostate Cancer Prostatic Dis 2005, 8:75-83.
71. Hayes TG: Pharmacologic treatment of male breast cancer. Exp Opin
Pharmacother 2009, 10:2499-2510.
72. Soon Wong N, Seong Ooi W, Pritchard KI: Role of gonadotropin-releasing
hormone analog in the management of male metastatic breast cancer is
uncertain. J Clin Oncol 2007, 25:3787.
73. Amin S, Zhang Y, Sawin CT, Evans SR, Hannan MT, Kiel DP, Wilson PW,
Felson DT: Association of hypogonadism and estradiol levels with bone
mineral density in elderly men from the Framingham study. Ann Intern
Med 2000, 133:951-963.
74. Szulc P, Munoz F, Claustrat B, Garnero P, Marchand F, Duboeuf F,
Delmas PD: Bioavailable estradiol may be an important determinant of
osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 2001,
86:192-199.
75. Khosla S, Melton LJ III, Atkinson EJ, O’Fallon WM, Klee GG, Riggs BL:
Relationship of serum sex steroid levels and bone turnover markers with
bone mineral density in men and women: a key role for bioavailable
estrogen. J Clin Endocrinol Metab 1998, 83:2266-2274.
76. Khosla S, Melton LJ III, Atkinson EJ, O’Fallon WM: Relationship of serum sex
steroid levels to longitudinal changes in bone density in young versus
elderly men. J Clin Endocrinol Metab 2001, 86:3555-3561.
77. Gennari L, Merlotti D, Martini G, Gonnelli S, Franci B, Campagna S, Lucani B,
Dal Canto N, Valenti R, Gennari C, Nuti R: Longitudinal association
between sex hormone levels, bone loss, and bone turnover in elderly
men. J Clin Endocrinol Metab 2003, 88:5327-5333.
78. Khosla S, Melton LJ III, Robb RA, Camp JJ, Atkinson EJ, Oberg AL,
Rouleau PA, Riggs BL: Relationship of volumetric BMD and structural
parameters at different skeletal sites to sex steroid levels in men. J Bone
Miner Res 2005, 20:730-740.
79. Sodergard R, Backstrom T, Shanbhag V, Carstensen H: Calculation of free
and bound fractions of testosterone and estradiol-17 beta to human
plasma proteins at body temperature. J Steroid Biochem 1982, 16:801-810.
80. Szulc P, Claustrat B, Munoz F, Marchand F, Delmas PD: Assessment of the
role of 17beta-oestradiol in bone metabolism in men: does the assay
technique matter? The MINOS study. Clin Endocrinol (Oxf) 2004,
61:447-457.
81. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS: Differential
effects of androgens and estrogens on bone turnover in normal men. J
Clin Endocrinol Metab 2003, 88:204-210.
82. Leder BZ, Finkelstein JS: Effect of aromatase inhibition on bone
metabolism in elderly hypogonadal men. Osteoporos Int 2005,
16:1487-1494.
83. Wickman S, Kajantie E, Dunkel L: Effects of suppression of estrogen action
by the p450 aromatase inhibitor letrozole on bone mineral density and
bone turnover in pubertal boys. J Clin Endocrinol Metab 2003,
88:3785-3793.
84. Burnett-Bowie SA, McKay EA, Lee H, Leder BZ: Effects of aromatase
inhibition on bone mineral density and bone turnover in older men
with low testosterone levels. J Clin Endocrinol Metab 2009, 94:4785-4792.
85. Hero M, Toiviainen-Salo S, Wickman S, Mäkitie O, Dunkel L: Vertebral
morphology in aromatase inhibitor-treated males with idiopathic short
stature or constitutional delay of puberty. J Bone Miner Res 2010,
25:1536-1543.
86. Hero M, Ankarberg-Lindgren C, Taskinen MR, Dunkel L: Blockade of
oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism,
insulin sensitivity and body composition. Eur J Endocrinol 2006,
155:453-460.
87. Hero M, Maury S, Luotoniemi E, Service E, Dunkel L: Cognitive effects of
aromatase inhibitor therapy in peripubertal boys. Eur J Endocrinol 2010,
163:149-155.
88. Cherrier MM, Matsumoto AM, Amory JK, Ahmed S, Bremner W, Peskind ER,
Raskind MA, Johnson M, Craft S: The role of aromatization in testosterone
supplementation: effects on cognition in older men. Neurology 2005,
64:290-296.
doi:10.1186/1477-7827-9-93
Cite this article as: de Ronde and de Jong: Aromatase inhibitors in men:
effects and therapeutic options. Reproductive Biology and Endocrinology
2011 9:93.
de Ronde and de Jong Reproductive Biology and Endocrinology 2011, 9:93
http://www.rbej.com/content/9/1/93
Page 7 of 7
